BLOC1S4: A Potential Drug Target and Biomarker for the Treatment of Lysosomal Storage Diseases

Target Name: BLOC1S4

NCBI ID: G55330

BLOC1S4

BLOC1S4: A Potential Drug Target and Biomarker for the Treatment of Lysosomal Storage Diseases

Lysosomal storage diseases are a group of genetic disorders characterized by the accumulation of dysfunctional or dysfunctional intracellular organelles, including lysosomes, in the cytoplasm of cells. These diseases can be caused by mutations in either the genes responsible for the formation of lysosomes or the genes involved in their catabolism. The consequences of lysosomal dysfunction can range from mild to severe, with the most severe cases leading to progressive neurodegeneration and even death.

BLOC1S4 is a protein that is expressed in a variety of tissues and is involved in the formation and maintenance of lysosomes. It is a subunit of the Biogenesis of Lysosome-related Organelles Complex (BLOC), which is a protein complex that is involved in the biogenesis of lysosomes. BLOC consists of four subunits: BLOC1S4, BLOC1S3, BLOC2S3, and BLOC2S1.

The BLOC1S4 subunit is a 21-kDa protein that is composed of 126 amino acid residues. It has a characteristic molecular structure that is composed of a long amino acid sequence that is involved in the formation of a hydrophobic domain, as well as a short amino acid sequence that is involved in the formation of a hydrophilic domain. The hydrophobic domain is responsible for the protein's stability, while the hydrophilic domain is responsible for its ability to interact with other proteins.

BLOC1S4 is involved in the formation of lysosomes by working with the protein BLOC2S1. When BLOC1S4 and BLOC2S1 are expressed in cells, they can form a complex that is responsible for the biogenesis of new lysosomes. This complex is thought to be involved in the regulation of lysosome dynamics and in the clearance of damaged or dysfunctional lysosomes.

As a drug target, BLOC1S4 is an attractive target for the treatment of lysosomal storage diseases because of its involvement in the formation and maintenance of lysosomes. By targeting the BLOC1S4 protein, researchers could potentially disrupt the formation of new lysosomes, which could lead to the clearance of damaged or dysfunctional lysosomes and the improvement of cellular function.

In addition to its potential as a drug target, BLOC1S4 is also a potential biomarker for the diagnosis and monitoring of lysosomal storage diseases. The formation of lysosomes is a critical event that is involved in the development and progression of these diseases, and disruptions in lysosome formation can be detected by measuring the levels of BLOC1S4 in cells. This could provide a valuable diagnostic tool for the assessment of lysosomal storage diseases and could help researchers to understand the underlying causes of these conditions.

Conclusion

BLOC1S4 is a protein that is involved in the formation and maintenance of lysosomes. As a potential drug target and biomarker, BLOC1S4 is an attractive target for the treatment of lysosomal storage diseases because of its involvement in these conditions. Further research is needed to fully understand the role of BLOC1S4 in lysosome formation and its potential as a drug and biomarker.

Protein Name: Biogenesis Of Lysosomal Organelles Complex 1 Subunit 4

Functions: Component of the BLOC-1 complex, a complex that is required for normal biogenesis of lysosome-related organelles (LRO), such as platelet dense granules and melanosomes. In concert with the AP-3 complex, the BLOC-1 complex is required to target membrane protein cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals. The BLOC-1 complex, in association with SNARE proteins, is also proposed to be involved in neurite extension. Plays a role in intracellular vesicle trafficking

The "BLOC1S4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BLOC1S4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets